Editorial
doi: 10.1001/jama.2017.19700.
Lack of Benefit With Idalopirdine for Alzheimer Disease: Another Therapeutic Failure in a Complex Disease Process
Affiliations
- PMID: 29318261
- DOI: 10.1001/jama.2017.19700
Item in Clipboard
Editorial
Lack of Benefit With Idalopirdine for Alzheimer Disease: Another Therapeutic Failure in a Complex Disease Process
JAMA.
.
No abstract available
Comment on
-
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.JAMA. 2018 Jan 9;319(2):130-142. doi: 10.1001/jama.2017.20373. JAMA. 2018. PMID: 29318278 Free PMC article. Clinical Trial.
Similar articles
-
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.Lancet Neurol. 2014 Nov;13(11):1092-1099. doi: 10.1016/S1474-4422(14)70198-X. Epub 2014 Oct 5. Lancet Neurol. 2014. PMID: 25297016 Clinical Trial.
-
Idalopirdine as a treatment for Alzheimer's disease.Expert Opin Investig Drugs. 2015;24(7):981-7. doi: 10.1517/13543784.2015.1052402. Epub 2015 May 28. Expert Opin Investig Drugs. 2015. PMID: 26022777 Review.
-
The 5-HT6 receptor antagonist idalopirdine potentiates the effects of donepezil on gamma oscillations in the frontal cortex of anesthetized and awake rats without affecting sleep-wake architecture.Neuropharmacology. 2017 Feb;113(Pt A):45-59. doi: 10.1016/j.neuropharm.2016.09.017. Epub 2016 Sep 16. Neuropharmacology. 2017. PMID: 27647493
-
Idalopirdine for Alzheimer's disease: written in the stars.Lancet Neurol. 2014 Nov;13(11):1063-1065. doi: 10.1016/S1474-4422(14)70232-7. Epub 2014 Oct 5. Lancet Neurol. 2014. PMID: 25297011 No abstract available.
-
Antagonism of the 5-HT6 receptor - Preclinical rationale for the treatment of Alzheimer's disease.Neuropharmacology. 2017 Oct;125:50-63. doi: 10.1016/j.neuropharm.2017.07.010. Epub 2017 Jul 12. Neuropharmacology. 2017. PMID: 28711518 Review.
Cited by
-
Lacticaseibacillus rhamnosus HA-114 and Bacillus subtilis R0179 Prolong Lifespan and Mitigate Amyloid-β Toxicity in C. elegans via Distinct Mechanisms.J Alzheimers Dis. 2024;101(1):49-60. doi: 10.3233/JAD-230948. J Alzheimers Dis. 2024. PMID: 39093068 Free PMC article.
-
Therapy for Alzheimer's disease: Missing targets and functional markers?Ageing Res Rev. 2021 Jul;68:101318. doi: 10.1016/j.arr.2021.101318. Epub 2021 Mar 9. Ageing Res Rev. 2021. PMID: 33711510 Free PMC article. Review.
-
Training the Workforce to Conduct Embedded Pragmatic Clinical Trials to Improve Care for People Living with Dementia and Their Caregivers.J Am Geriatr Soc. 2020 Jul;68 Suppl 2(Suppl 2):S21-S27. doi: 10.1111/jgs.16615. J Am Geriatr Soc. 2020. PMID: 32589278 Free PMC article.
-
MIND food and speed of processing training in older adults with low education, the MINDSpeed Alzheimer's disease prevention pilot trial.Contemp Clin Trials. 2019 Sep;84:105814. doi: 10.1016/j.cct.2019.105814. Epub 2019 Jul 18. Contemp Clin Trials. 2019. PMID: 31326523 Free PMC article.
-
Neem Derivatives Inhibits Tau Aggregation.J Alzheimers Dis Rep. 2019 Jun 14;3(1):169-178. doi: 10.3233/ADR-190118. J Alzheimers Dis Rep. 2019. PMID: 31259310 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
